Physicians' Academy for Cardiovascular Education

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Christoph Wanner, MD - University of Würzburg, Germany - Online CME

Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.

Video navigation menu

  • EMPA-REG OUTCOME: eGFR over 3 years 02:32
  • New onset or worsening of nephropathy 04:20
  • Outcome in patients with pre-existing CKD (renal population)  08:28
  • New onset or worsening of nephropathy: subgroup analysis  10:06
  • Safety 12:30

Educational information

This lecture was part of a CME accredited symposium: Epigenetics in CKD & CVD: A potential breakthrough therapy? held at ERA-EDTA in Copenhagen, Denmark.


Professor Christoph Wanner, MD - University of Würzburg, Germany


This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.


Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

View slides of prof. Wanner


This is available as accredited online CME for members. Click the button below to enroll:

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: